Drug Class
- Highly selective α₂-adrenergic receptor agonist
- α₂:α₁ selectivity ≈ 1600:1 (much higher than clonidine)
Mechanism of Action
Dexmedetomidine acts primarily at central α₂A receptors, producing:
- Sedation
- Locus coeruleus inhibition → ↓ norepinephrine release
- Produces a “cooperative” or arousable sedation resembling natural non-REM sleep
- Minimal cortical depression
- Analgesia (opioid-sparing)
- Spinal cord α₂ activation → inhibition of substance P and glutamate release
- Sympatholysis
- ↓ sympathetic tone → ↓ HR and BP
- Anxiolysis
- Central adrenergic inhibition without GABAergic effects
Pharmacokinetics
| Parameter |
Details |
| Administration |
IV infusion (FDA-approved); off-label intranasal, oral, buccal |
| Onset |
5–10 min (IV) |
| Distribution |
Highly lipophilic; Vd ~1.3–2 L/kg |
| Protein Binding |
~94% |
| Metabolism |
Extensive hepatic metabolism (UGT1A4, UGT2B10, CYP2A6) |
| Elimination |
Renal (metabolites) |
| Half-life |
~2–3 hours (context-sensitive half-time increases with prolonged infusion) |
Pharmacodynamics (Key Clinical Point)
- Sedation without respiratory depression
- Patients remain easily arousable and interactive
- Distinct from GABAergic sedatives (propofol, benzodiazepines)
Indications
FDA-Approved
- ICU sedation for initially intubated and mechanically ventilated patients
- Procedural sedation (non-intubated)
Common Off-Label Uses
- ICU delirium prevention/treatment
- Alcohol withdrawal (adjunct)
- Opioid- and benzodiazepine-sparing sedation
- Pediatric sedation
- Perioperative sympatholysis
- Withdrawal management (opioids, benzos)
Dosing (IV)
ICU Sedation
- Infusion: 0.2–0.7 mcg/kg/hr
- Some centers titrate up to 1.5 mcg/kg/hr (off-label)
Loading Dose
- 1 mcg/kg over 10 min (often avoided due to bradycardia/hypotension)
Adverse Effects
Cardiovascular (dose- and rate-dependent)
- Bradycardia
- Hypotension
- Transient hypertension (from peripheral α₂B stimulation with rapid bolus)
Other
- Dry mouth
- Nausea
- Withdrawal (rebound hypertension, agitation if abruptly stopped after prolonged use)
Contraindications / Cautions
- Advanced heart block (without pacemaker)
- Severe ventricular dysfunction
- Hypovolemia
- Concomitant negative chronotropes (β-blockers, digoxin, non-DHP CCBs)
Drug Interactions
- Additive bradycardia/hypotension with:
- β-blockers
- Opioids
- Propofol
- Minimal CYP inhibition → low interaction burden compared to many sedatives
Comparison to Other Sedatives
| Feature |
Dexmedetomidine |
Propofol |
Benzodiazepines |
| Respiratory depression |
Minimal |
Significant |
Moderate |
| Delirium risk |
↓ |
Neutral |
↑ |
| Analgesia |
Mild |
None |
None |
| Sedation type |
Cooperative |
Deep |
Anxiolytic/sedative |
| Mechanism |
α₂ agonist |
GABA-A |
GABA-A |
Clinical Pearls (Pharmacist-Focused)
- Ideal for light sedation targets (RASS −1 to 0)
- Avoid abrupt discontinuation after prolonged infusions (>48–72 h)
- Can reduce opioid and benzodiazepine requirements
- Monitor HR and BP closely, especially during initiation and titration
- Not reliable for deep sedation or paralysis-required scenarios
